Biopharmaceutical company BioArctic said it has signed an expanded research collaboration agreement with Uppsala University in Sweden for the further development of antibody-based PET imaging of the brain in patients with Alzheimer's disease.
The agreement expands on an ongoing collaboration between BioArctic and Uppsala University that has been focusing on developing a new type of PET ligand aimed at improving brain imaging. The company believes antibody-based PET ligands can provide additional information over that of currently available PET ligands.
BioArctic will now provide financial support for a three-year research position at Uppsala University, with potential for an extension.
